BioWorld

Aug. 1, 2006

Predix In Potential $307.5M Collaboration With Amgen

In its first major partnership, Predix Pharmaceuticals Holdings Inc. could receive more than $307.5 million per terms of a new deal with Amgen Inc. on S1P1 modulators for autoimmune diseases. (BioWorld Today) Read More

YM Secures Japanese Partner For EGFR-Inhibitor In Cancer

Still Turning: Racial Profiling, Harassment, VC Execs Get Hip

Pandemic Planning: Not 'Out Of The Woods' Despite Good News

FDA Mulling Plan B OTC Sales For Those 18, Older

Opting For An LSE Listing, Napo Raises £11.9M In IPO

Receptor BioLogix Acquires Failed Aphton Cancer Drug

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 22, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...